Immunohistochemical detection of DNA topoisomerase II alpha, P-glycoprotein and multidrug resistance protein in small-cell and non-small-cell lung cancer
1998

Differences in Drug Resistance in Lung Cancer Types

Sample size: 56 publication Evidence: moderate

Author Information

Author(s): J Kreisholt, M Sorensen, PB Jensen, BS Nielsen, CB Andersen, M Sehested

Primary Institution: Rigshospitalet, Copenhagen, Denmark

Hypothesis

The study aims to investigate the expression of topoisomerase II alpha, P-glycoprotein, and multidrug resistance protein in small-cell and non-small-cell lung cancer.

Conclusion

The study found that non-small-cell lung cancer has significantly lower levels of topoisomerase II alpha compared to small-cell lung cancer, which may explain the differences in their responses to treatment.

Supporting Evidence

  • Non-small-cell lung cancer had significantly less topoisomerase II alpha than small-cell lung cancer.
  • Only 5 out of 27 non-small-cell lung cancer cases had more than 5% positive cells for topoisomerase II alpha.
  • After treatment, there was an increase in P-glycoprotein and multidrug resistance protein positivity in small-cell lung cancer.

Takeaway

This study looked at two types of lung cancer and found that one type is much less responsive to certain drugs because it has less of a key protein that those drugs target.

Methodology

Immunohistochemical analysis was performed on paraffin-embedded tissue from 27 cases of untreated non-small-cell lung cancer and 29 cases of untreated small-cell lung cancer.

Limitations

The study included a small sample size and was retrospective in nature.

Participant Demographics

The SCLC patients had a mean age of 57 years with an equal male-female ratio.

Statistical Information

P-Value

p<0.0001

Statistical Significance

p<0.0001

Want to read the original?

Access the complete publication on the publisher's website

View Original Publication